Virus in Biological Technology

Eiger BioPharmaceuticals Acquires Exclusive License to Novel Hepatitis C Virus (HCV) Technology From Stanford University

PALO ALTO, Calif., August 4, 2009 /PRNewswire/ -- Eiger BioPharmaceuticals, Inc., a biotechnology company developing antiviral therapies, announced today that it has licensed the exclusive worldwide rights to novel Hepatitis C Virus (HCV) technology from Stanford University. This te...

ImmuneRegen BioSciences Confirms Homspera's Therapeutic Anti-Influenza Effect on Pandemic H1N1 Influenza Virus After Oral Administration

SCOTTSDALE, Ariz., July 29 /PRNewswire-FirstCall/ -- ImmuneRegen BioSciences(R), a wholly owned subsidiary of IR BioSciences Holdings, Inc. (OTC Bulletin Board: IRBS), reports preliminary evidence that its selective Neurokinin 1-receptor agonist Homspera(R) is both active on ora...

Novavax Announces Selection of a Respiratory Syncytial Virus Vaccine Candidate for Advanced Preclinical Studies

ROCKVILLE, Md., July 22 /PRNewswire-FirstCall/ -- Novavax, Inc. (Nasdaq: NVAX ) announced today final selection of a Respiratory Syncytial Virus (RSV) vaccine candidate that will be advanced into additional preclinical studies to support an Investigational New Drug (IND) applicati...

Solon Manufacturing Company Acquires PurFybr Brands; Adds Influenza Virus Diagnostic Swabs to Product Line

NORTH HAVEN, Conn., June 19 /PRNewswire/ -- Solon Manufacturing Co., a leading maker of single use disposable products for the medical, industrial and diagnostic fields, today announced its acquisition of certain assets of PurFybr Inc. The purchase, which specifically includes PurFybr brand right...

Three Rivers Announces Positive Results from Phase 3 DIRECT Trial of Once-Daily INFERGEN(R) with Ribavirin in Hepatitis C Virus Treatment Failures

WARRENDALE, Pa., June 16 /PRNewswire/ -- Three Rivers Pharmaceuticals announced today positive results of the U.S.-based, randomized Daily-Dose Consensus Interferon and Ribavirin: Efficacy of Combined Therapy (DIRECT) clinical trial authored by Bruce R. Bacon, M.D., of Saint Louis University , an...

Sinovac Completes Construction of H1N1 Virus Seed Bank

Production of Seasonal Influenza Vaccine Is Nearly Completed BEIJING, June 15 /PRNewswire-Asia/ -- Sinovac Biotech Ltd. (NYSE Amex: SVA ), a leading developer and provider of vaccines in China, announced today that it has completed construction of the H1N1 virus seed bank necessary to produ...

Lethality of H1N1 Influenza Virus Increasing According to Latest Analysis of Virus Peptide Genomic Data

Boston Biotech Firm Reports First Rise in 76 Years of Replikin Count* of H1N1 Lethality Gene BOSTON, June 10 /PRNewswire/ -- An analysis of the latest peptide genomic data for the H1N1 influenza virus indicates that the current global outbreak of H1N1 is increasing in its capacity for lethali...

Sanofi Pasteur Receives Seed Virus to Produce New Influenza A(H1N1) Vaccine

- Company to take first steps toward large-scale production - SWIFTWATER, Pa. and LYON, France, May 27 /PRNewswire-FirstCall/ -- Sanofi Pasteur, the vaccines division of the sanofi-aventis Group (EURONEXT: SAN and NYSE: SNY ), announced today it has received the new influenza A(H1N1) seed v...

Biotechnology Company, Replikins Ltd., Provided Advance Warning of Mexican H1N1 'Swine Flu' Virus Outbreak

BOSTON, April 27 /PRNewswire/ -- Replikins Ltd. published a FluForecast(R) warning in April 7th, 2008, a year before the recent Mexico and California H1N1 cases. The company was able to state the likelihood of H1N1 outbreaks based on its patented Replikin Count(TM) genomics technology, which exami...

Biotechnology Company Provided Advance Warning of Mexican H1N1 "Swine Flu" Virus Outbreak

Replikins, Ltd. published a FluForecast® warning in April 7th, 2008, a year before the recent Mexico and California H1N1 cases. The company was able to state the likelihood of H1N1 outbreaks based on its patented Replikin Count™ genomics technology, which examines specific regions in v...

MIT virus battery could power cars, electronic devices

CAMBRIDGE, Mass--For the first time, MIT researchers have shown they can genetically engineer viruses to build both the positively and negatively charged ends of a lithium-ion battery. The new virus-produced batteries have the same energy capacity and power performance as state-of-the-art recha...

ImQuest Presents Data on the Anti-Hepatitis B Virus Activity of Pyrimidinediones at the 13th ISVHLD Meeting in Washington D.C.

FREDERICK, Md., March 31 /PRNewswire/ -- ImQuest Life Sciences today presented important new results on the continued development of the pyrimidinedione small molecules as antiviral agents at the 13th International Symposium on Viral Hepatitis and Liver Disease meeting held last week in Washington...

Oncolytics Biotech(R) Inc. Collaborators Present Reovirus Research at Replicating Oncolytic Virus Meeting

CALGARY, March 23 /PRNewswire-FirstCall/ - Oncolytics Biotech Inc. (TSX: ONC, NASDAQ: ONCY ) announced results of two preclinical studies that were presented at the Fifth International Meeting on Replicating Oncolytic Virus Therapeutics. The meeting was held in Banff, Alberta from March 18th to ...

Nature Medicine study shows Peregrine's bavituximab can cure lethal virus infections

TUSTIN, Calif., November 23, 2008 -- Peregrine Pharmaceuticals, Inc. (NASDAQ: PPHM) today reported publication of data in Nature Medicine that supports the broad anti-viral potential of the company's novel anti-phosphatidylserine (anti-PS) antibody platform, showing that its PS-targeting drug ba...

Oncolytics Biotech(R) Inc. Collaborators Update Combination REOLYSIN(R) and Docetaxel Trial Results at Replicating Oncolytic Virus Meeting

CALGARY, March 20 /PRNewswire-FirstCall/ - Oncolytics Biotech Inc. (TSX: ONC, NASDAQ: ONCY ) today announced updated clinical results from its U.K. combination REOLYSIN(R) and docetaxel clinical trial for patients with advanced cancers. The principal investigator for the trial is Professor Harde...

AcroMetrix Announces the Release of OptiQuant-S Hepatitis C Virus (HCV) Panel

BENICIA, Calif., March 3 /PRNewswire/ -- AcroMetrix, a leading manufacturer of molecular quality control standards and controls for clinical diagnostic and blood testing laboratories, announced today the release of the OptiQuant-S HCV RNA Quantification Panel. This new panel utilizes AcroMetrix's...

NOVAVAX Announces Preclinical Study Results for a Respiratory Syncytial Virus ('RSV') Vaccine Candidate Directed Against the Fusion (F) Protein

Preclinical Study Shows the Investigational RSV-F Virus-like Particle Vaccine Induced Neutralizing Antibodies and Protected Mice upon Challenge ROCKVILLE, Md., Feb. 27 /PRNewswire-FirstCall/ -- Novavax, Inc. (Nasdaq: NVAX ) announced results from a preclinical study of a Respiratory Syncyti...

Hepatitis C Virus Patient Opportunity Exists Within Many of the Major U.S. Local Markets

However, Insurance Coverage of Hepatitis C Patients Is Skewed Towards Medicare and Medicaid Compared With Dominance of Private Coverage in the General Population, According to a New Analytics Tool From Decision Resources WALTHAM, Mass., Feb. 12 /PRNewswire/ -- Decision Resources, one of the w...

Vaccine Against the Chikungunya Virus in Development by a Public-Private Partnership

LEIDEN, The Netherlands, February 4 /PRNewswire/ -- Top Institute Pharma (TI Pharma) has formed a consortium with Wageningen University, Erasmus University Medical Centre and Nobilon, a subsidiary of Schering-Plough, to develop a 'proof of concept' vaccine against the Chikungunya virus. This...

Novavax and Vivalis Sign a Research License Agreement to Use the EB66(R) Cell Line for the Production of Virus Like Particle Based Vaccines

ROCKVILLE, Md. and NANTES, France, Feb. 4 /PRNewswire-FirstCall/ -- NOVAVAX (Nasdaq: NVAX ) and Vivalis (NYSE Euronext: VLS) announced today the completion of a research license to use the Vivalis proprietary EB66(R) cell line, for the production of Novavax VLP based vaccines. Through this colla...

Nature Medicine study shows Peregrine's bavituximab can cure lethal virus infections

TUSTIN, Calif., November 23, 2008 -- Peregrine Pharmaceuticals, Inc. (NASDAQ: PPHM) today reported publication of data in Nature Medicine that supports the broad anti-viral potential of the company's novel anti-phosphatidylserine (anti-PS) antibody platform, showing that its PS-targeting drug ba...

NOVAVAX and the University of Massachusetts Medical School Announce Preclinical Study Results for a Respiratory Syncytial Virus ('RSV') Vaccine Candidate

ROCKVILLE, Md., Dec. 9 /PRNewswire-FirstCall/ -- Novavax, Inc. (Nasdaq: NVAX ) and the University of Massachusetts Medical School announced results from a preclinical study of a Respiratory Syncytial Virus ("RSV") vaccine candidate. Novavax has licensed exclusive worldwide rights from the Un...

A New Way to Predict Outbreaks: Replikin Peptide Concentration in H5N1 Influenza Virus Genome as a Marker for Lethal Outbreaks

BOSTON, Nov. 12 /PRNewswire/ -- WHO and CDC have stated that the predictive accuracy of their annual formulations for human influenza vaccines is "suboptimal" -- often correct less than 50% of the time, especially for seniors. Perhaps in part because we are not yet accurate in our predictions ...

Improved culture system for hepatitis C virus infection

A University of California, San Diego School of Medicine researcher has developed the first tissue culture of normal, human liver cells that can model infection with the Hepatitis C virus (HCV) and provide a realistic environment to evaluate possible treatments. The novel cell line, described in ...

ZyGEM and DIAGNOTEC Collaborate on Diagnostics for Detecting a Devastating Virus Attacking Salmon

- Improved Technology Will Provide the Early Detection Critical to Prevent IPN Viral Spread in Fish Farms and Wild Stocks - HAMILTON, New Zealand, SOLANA BEACH, Calif. and SANTIAGO, Chile, June 17 /PRNewswire/ -- ZyGEM Corp Ltd. and DIAGNOTEC S.A. today announced they have entered in...

H1N1 Influenza Virus With Highest Replikin Count(TM) Since the 1918 Pandemic Identified in the U.S. and Austria

BOSTON, April 7, 2008 /PRNewswire/ -- Replikins Ltd. has found that the Replikin Count(TM) of the H1N1 strain of influenza virus has recently increased to 7.6 (plus/minus 1.4), its highest level since the 1918 H1N1 pandemic (p value less than 0.001). A rising Replikin Count of a particular inf...

AMDL Signs Exclusive Licensing Agreement for Human Papilloma Virus Diagnostic Test Kit in Certain Asian Countries

TUSTIN, Calif., April 3, 2008 /PRNewswire-FirstCall/ -- AMDL, Inc. (Amex: ADL ), headquartered in Tustin, California, with operations in Shenzhen, Jiangxi, and Jilin, China, is a vertically integrated specialty pharmaceutical company. In combination with its subsidiary Jade Pharmaceutical Inc...

Lethal Human H5N1 Influenza Virus Replikin Gene Still Upregulated

BOSTON, Dec. 11 /PRNewswire/ -- Replikins Ltd. today announced its latest findings regarding the virus replikin count in human H5N1 influenza virus. The company's software-driven analysis has found that the prevalence of these sequences has remained high in Indonesia; in addition, higher count...

Pharmasset and Roche to Present R7128 Data at the 14th International Symposium on Hepatitis C Virus and Related Viruses

PRINCETON, N.J., Sept. 6 /PRNewswire-FirstCall/ -- Pharmasset, Inc. (Nasdaq: VRUS ) and Roche (OTC: RHHBY) announced today that four scientific presentations related to R7128 for the treatment of chronic hepatitis C virus (HCV) will be made at the 14th International Symposium on Hepatitis C V...

MacroGenics Announces the Initiation of a Phase 2 Clinical Trial to Evaluate the Safety and Efficacy of Monoclonal Antibody MGAWN1 in Subjects with Suspected Central Nervous System Infection Due to West Nile Virus

ROCKVILLE, Md. , July 13 /PRNewswire/ -- MacroGenics, Inc. today announced the initiation of the PARADIGM trial, a Phase 2 clinical study evaluating MGAWN1, a humanized monoclonal antibody, for the treatment of individuals with suspected central nervous system infection due to West Nile Viru...

Mach One Corporation Developing a Nasal, Hand Carried Product as Solution to Swine Flu (H1N1) Virus

Product Will Create A Barrier To Block The Attachment Of The Virus To The Nasal Membranes BELGIUM, Wis., June 4 /PRNewswire-FirstCall/ -- Mach One Corporation (Pink Sheets: MNCN), an innovative, global wellness solutions company, announces the development of a nasal immunoglobulins based pr...

Novavax and the NIH Agree to Evaluate a Virus-like Particle (VLP) Vaccine Candidate Against the Novel Influenza A (H1N1) Virus

Company completes initial steps towards producing Influenza A (H1N1) VLP vaccine for animal and human testing ROCKVILLE, Md., June 4 /PRNewswire-FirstCall/ -- Novavax, Inc. (Nasdaq: NVAX ) and the Division of Microbiology and Infectious Diseases (DMID) of the National Institute of Allergy a...

Germgard's Ultra-Fast Hand Hygiene Solution Protects Against Deadly MRSA, C difficile, and Influenza Virus

DOVER, N.J., April 29 /PRNewswire/ -- In an effort to provide technology to reduce healthcare-associated infections, Germgard Lighting LLC, a New Jersey-based early-phase medical device company, has demonstrated its patented ultra-fast (~1 second) hand hygiene solution. The solution is designed to...

Beckman Coulter Acquires Rights to Hepatitis C Virus

Enables Development of Molecular Quantitative Viral Load Assay ORANGE COUNTY, Calif., April 30 /PRNewswire-FirstCall/ -. Beckman Coulter, Inc. (NYSE: BEC ) announced today that it has licensed certain rights to testing for the hepatitis C virus (HCV) from Siemens Healthcare Diagnostics. ...

Replikins Oral Vaccine Synthesized in 7 Days Protects 91% of Shrimp Against a Lethal Virus

BOSTON, March 11 /PRNewswire/ -- Replikins, Ltd. has announced development of a chemically synthesized vaccine specific to a Taura Syndrome virus structure based on its patented Replikins(TM) technology. When the vaccine was administered orally to shrimp, 91% survived a challenge by the lethal...

New Web virus could lead to lost files, extortion

Security experts are urging Web users to watch out for a new online scam a virus that security experts say can lock up files on your computer, after which the creator demands $200 for the code to get them back. Websense Inc. in San Diego first noticed the virus after it hit a client who visited...

"Dasher" virus can turn off security applications

A computer virus named Dasher has become a greater threat with the spread of a new version that can turn off anti-virus applications and allow remote access to computer systems, security experts say. An earlier version of the virus was not as effective at infecting computers because of poor code. D...

Securitas aims to counter virus behavior

Madison, Wis. - Profit-driven hackers, armed with increasingly sophisticated malicious software, have caused over $8 billion in damage to corporation computer systems this year alone, and variations of existing viruses are proliferating faster than ever before. Fortunately for beleagured business...

Prodesse begins clinical trials for flu virus detection

Waukesha, Wis. - Several major healthcare institutions have begun clinical trials on a flu detection product developed by Prodesse, Inc. , a Waukesha-based biotechnology company. The product, known as ProFlu+, is being billed as a more complete and user-friendly test to help laboratories det...

UW computer scientists fighting computer virus "Cold War"

Editor's note : This article first appeared on the UW Business News Wire . Madison, Wis. - First came the virus. Then came the antivirus software. Ever since, virus programmers have been escalating their technology, trying to stay one step ahead of the computer security engi...